Market revenue in 2023 | USD 14.2 million |
Market revenue in 2030 | USD 33.4 million |
Growth rate | 13% (CAGR from 2023 to 2030) |
Largest segment | Growth hormone deficiency |
Fastest growing segment | Small for Gestational Age |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Other Applications, Growth Hormone Deficiency |
Key market players worldwide | Novo Nordisk A/S ADR, Eli Lilly and Co, Pfizer Inc, Sandoz Group AG ADR, Roche, Ferring, Ipsen SA, Teva Pharmaceutical Industries Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to human growth hormone market will help companies and investors design strategic landscapes.
Growth hormone deficiency was the largest segment with a revenue share of 51.41% in 2023. Horizon Databook has segmented the Kuwait human growth hormone market based on turner syndrome, idiopathic short stature, prader-willi syndrome, small for gestational age, other applications, growth hormone deficiency covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Kuwait human growth hormone market , including forecasts for subscribers. This country databook contains high-level insights into Kuwait human growth hormone market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account